
ADC patritumab deruxtecan shows promising efficacy in heavily pretreated EGFR-mutated NSCLC patients.


coremsg

Patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy may have meaningful and durable responses to a novel antibody-drug conjugate HER3-DXd, new phase 2 data suggest.

Novel ADC Offers Hope in Heavily Pretreated NSCLC

novel-adc-patritumab-deruxtecan-shows-promise-in-heavily-pretreated-egfr-mutated-nsclc


Novel ADC Patritumab Deruxtecan Shows Promise in Heavily Pretreated EGFR-Mutated NSCLC
